|
Fernández-Pérez MP, Montenegro MF, Sáez-Ayala M, Sánchez-del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN. Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma. Neoplasia. 2013 Jul;15(7):826-39. PubMed PMID: 23814494; PubMed Central PMCID: PMC3689245.
AÑO: 2013; IF: 5.398
|
23814494
|
Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. PubMed PMID: 23792190.
AÑO: 2013; IF: 26.602
|
|
Montenegro MF, Sánchez-del-Campo L, Fernández-Pérez MP, Sáez-Ayala M, Cabezas-Herrera J, Rodríguez-López JN. Targeting the epigenetic machinery of cancer cells. Oncogene. 2015 Jan 8;34(2):135-43. doi: 10.1038/onc.2013.605. Review. PubMed PMID: 24469033.
AÑO: 2015; IF: 7.932
|
|
Sánchez-del-Campo L, Rodríguez-López JN. Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin. Int J Cancer. 2008 Nov 15;123(10):2446-55. doi: 10.1002/ijc.23813. PubMed PMID: 18729182.
AÑO: 2008; IF: 4.734
|
|
Montenegro MF, González-Guerrero R, Sánchez-del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN. Targeting the epigenetics of the DNA damage response in breast cancer. Cell Death Dis. 2016 Apr 7;7:e2180. doi: 10.1038/cddis.2016.85. PubMed PMID: 27054335; PubMed Central PMCID: PMC4855664.
AÑO: 2016; IF: 5.965
|